Advertisement

Topics

FDA Approves Castration-Sensitive Prostate Cancer Drug

16:18 EST 8 Feb 2018 | Pharmacy Times

Officials with the FDA have granted approval to abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC), according to a press release.

Original Article: FDA Approves Castration-Sensitive Prostate Cancer Drug

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Castration-Sensitive Prostate Cancer Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...